1651-2227/asset/olbannercenter.gif?v=1&s=aed7f4736e780f26e96740fe0c8faf09ec8d2946)
Successful treatment of persistent pulmonary hypertension of the newborn with bosentan
Article first published online: 11 JUN 2009
DOI: 10.1111/j.1651-2227.2009.01386.x
© 2009 The Author(s)/Journal Compilation © 2009 Foundation Acta Pædiatrica
Additional Information
How to Cite
Nakwan, N., Choksuchat, D., Saksawad, R., Thammachote, P. and Nakwan, N. (2009), Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatrica, 98: 1683–1685. doi: 10.1111/j.1651-2227.2009.01386.x
Publication History
- Issue published online: 1 SEP 2009
- Article first published online: 11 JUN 2009
- Received 7 March 2009; revised 20 March 2009; accepted 19 May 2009.
- Abstract
- Article
- References
- Cited By
Keywords:
- Bosentan;
- Newborn infant;
- Persistent pulmonary hypertension of the newborn
Abstract
The sophisticated and expensive treatment modalities of persistent pulmonary hypertension of the newborn (PPHN), such as nitric oxide, are limited in developing countries. Alternative (less expensive) treatments are being sought and bosentan, an oral dual endothelin-1 receptor antagonist, may be an option for the treatment of PPHN. We report our experience of using bosentan in a neonate with severe PPHN.
Conclusion: Bosentan may be a useful adjuvant therapy in neonates with PPHN, providing significant improvement in oxygenation, and thus may be particularly useful in the treatment of PPHN in countries with limited resources.